Immusoft
PrivateLast Round
Grant
Mar 30, 2026
Total Funding Raised
$89.62M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Immusoft operates in Healthcare & Life Sciences and is based in Seattle, Washington. Its latest recorded funding round was a Grant round in March 2026.
Immusoft is a biotechnology company that develops autologous cell therapies utilizing its proprietary Immune System Programming (ISP™) platform to transform patients' B cells into biofactories for the sustained delivery of therapeutic proteins.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immusoft Comparables
Compare Immusoft with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Be Biopharma | 83% | |
| Bespoke Biotherapeutics | 80% | |
| Sangamo Therapeutics Inc | 76% |
For institutional investors. Book with your work email.
Immusoft Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 30, 2026 | ||||
| Grant | Jan 26, 2023 | ||||
| Grant | Nov 29, 2021 | ||||
| Grant | Sep 25, 2020 | ||||
| Series B | Sep 25, 2020 | ||||
Series B | Jan 3, 2019 |
For institutional investors. Book with your work email.
Immusoft Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Mesa Verde Venture Partners | Series B |
| EB Research Partnership | Series A |
| Thiel Foundation | Grant |
| NIH RADx | Grant |
| Founders Fund | Series B, Series A |
| Technium | Series A |
| Ikarian Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors grew 40% MoM.
- Mar 30, 2026
$15M grant funding secured.
For institutional investors. Book with your work email.
Immusoft Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Immusoft's valuation, stock price, and market status.
Is Immusoft a public or private company?
Immusoft is a private company.
What is the current stock price of Immusoft?
Immusoft is a private company, so its shares have no public market price. Caplight tracks Immusoft's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Immusoft worth (valuation)?
Valuation information for Immusoft is not publicly available.
Can I buy Immusoft stock?
Immusoft shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Immusoft's last funding round?
Immusoft's most recent funding round was Grant on March 30, 2026.
Who are the main investors in Immusoft?
Key investors in Immusoft include NIH RADx, Technium, 600 Mile Challenge Fund, Breakout Ventures, California Institute for Regenerative Medicine.
Will Immusoft IPO soon?
No public IPO plans have been announced for Immusoft.
How can I track Immusoft secondary market activity?
Caplight tracks bids, offers, and trades in Immusoft's shares on secondary markets.